New dopamine agonist pramipexole improves Parkinsonism and depression in Parkinson's disease

Hiroshima Journal of Medical Sciences

Volumn 60, Issue 4, 2011, Pages 79-82

  Harada, Toshihide ^a   Ishizaki, Fumiko ^a   Horie, Nobuko ^b   Nitta, Yumiko ^c   Yamada, Tohru ^d   Sasaki, Tomohiro ^d   Nagakane, Tomoomi ^d   Yasumatsu, Yoshiteru ^d   Nitta, Kohsaku ^e   Katsuoka, Hiroyuki ^f  

^a PREFECTURAL UNIVERSITY OF HIROSHIMA   (Japan)

^b National Hospital Organization   (Japan)

^c Suzugamine Women's College   (Japan)

^d Yamada Memorial Hospital   (Japan)

^e Shiraki no Sato   (Japan)

^f HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

Author keywords

Depression; HAMD; MADRS; Parkinson's disease; Pramipexole; UPDRS

Indexed keywords

BENSERAZIDE; CABERGOLINE; CARBIDOPA; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; SELEGILINE; TALIPEXOLE; THREO 3,4 DIHYDROXYPHENYLSERINE; TRIHEXYPHENIDYL;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DEPRESSION; EVIDENCE BASED MEDICINE; FEMALE; GAIT DISORDER; HAMILTON SCALE; HUMAN; HYPOKINESIA; JAPANESE; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PARKINSON DISEASE; PARKINSONISM; SCORING SYSTEM; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 84857248377     PISSN: 00182052     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Barone, P., Poewe, W., Albrecht, S., Debieuvre, C., Massey, D., Rascol, O., Tolosa, E. and Weintraub, D. 2010. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. The Lancet Neurology 9: 573-580.
2. Black, K.J. 2002. A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonist. Proc. Natl. Acad. Sci. USA 99: 17113-17118. (Pubitemid 36034107)
3. Brown, R.G. 1988. Depression and disability in Parkinson's disease: a follow-up of 132 cases. Psychol. Med. 18: 49-55. (Pubitemid 18071632)
4. Corrigan, M.H., Denahan, A.Q., Wright, C.E., Ragual, R.J. and Evans, D.L. 2000. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depression and Anxiety 11: 58-65. (Pubitemid 30228411)
5. Dooneief, G. 1992. An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch. Neurol. 49: 305-307.
6. Harada, T., Ishizaki, F., Murata, Y., Mitsuoka, K., Kumagai, R. and Nitta, K. 2001. Clinical characteristics of neuroleptic malignant syndrome in Parkinson's disease and other neurological disorders. International Medical Journal 8: 249-258.
7. Harada, T., Ishizaki, R, Tachiki, N., Nitta, K., Horie, N. and Matsumoto, T. 2001. Evaluation of cardiovascular circadian rhythm in patients with Parkinson's disease. International Medical Journal 8: 269-274. (Pubitemid 34131978)
8. Kano, O., IKeda, K., Kiyozuka, T., Iwamoto, K., Ito, H., Kawase, Y., Sato, R., Fujioka, T., Araki, Y., Baba, S. and Iwasaki, Y. 2008. Beneficial effect of pramipexole for motor function and depression in Parkinson's disease. Neuropsychiatr. Dis. Treat. 4: 707-710.
9. Linazasoro, G. 2004. Conversion from dopamine agonists to pramipexole: an open-label trial in 227 patients with advanced Parkinson's disease. J. Neurol. 251: 335-339. (Pubitemid 38387153)